Response to treatment over 48 weeks
| Baseline Median (IQ3-151 range) |
12 Weeks Median (IQ range) |
24 Weeks Median (IQ range) |
48 Weeks Median (IQ range) | |
| Gold (n=72) | ||||
| ESR3-151 (mm/1st h) | 39 (18–57) | 22 (12–44) | 28 (10–41) | 24 (9–52)3-160 |
| CRP3-151 (IU/l) | 31 (11–77) | 14 (10–37) | 10 (9–33) | 16 (9–40)3-160 |
| RAI3-151 | 12 (6–18) | 6 (3–12) | 5 (2–9) | 4 (1–10)3-160 |
| Pain score | 62 (42–76) | 54 (31–76) | 42 (24–65) | 50 (15–75)3-160 |
| HAQ3-151 | 2.0 (1.5–2.375) | 2.0 (1.261–2.5) | 1.875 (1.375–2.375) | 1.937 (1.3–2.5) |
| EMS3-151 (min) | 60 (25–240) | 45 (10–120) | 60 (10–105) | 45 (2–90)3-160 |
| GWB3-151, No (%) good or v good | 26 (36) | 21 (29) | 23 (32) | 24 (33) |
| Methotrexate (n=69) | ||||
| ESR (mm/1st h) | 46 (30–68) | 40 (20–62) | 31 (18–51) | 24 (16–44) 3-160 |
| CRP (IU/l) | 33 (14–59) | 18 (10–36) | 18 (10–37) | 10 (9–25) 3-160 |
| RAI | 11 (6–16) | 7 (4–13) | 6 (3–10) | 5 (2–10)3-160 |
| Pain score | 71 (50–76) | 50 (46–70) | 50 (35–65) | 50 (29–70)3-160 |
| HAQ | 2 (1.5–2.5) | 2 (1.562–2.25) | 1.875 (1.562–2.375) | 1.875 (1.25–2.25) |
| EMS (min) | 60 (30–120) | 60 (30–90) | 30 (15–60) | 30 (10–60) |
| GWB, No (%) good or v good | 20 (29) | 14 (20) | 27 (39) | 24 (35) |